Effects of a six-month yoga intervention on the immune-inflammatory pathway in antipsychotic-stabilized schizophrenia patients: A randomized controlled trial

Asian J Psychiatr. 2023 Aug:86:103636. doi: 10.1016/j.ajp.2023.103636. Epub 2023 May 24.

Abstract

Background: Schizophrenia is a complex neuropsychiatric disorder for which several etiopathological theories have been proposed, one of the prominent ones being immune dysfunction. Recent studies on yoga as an add-on therapy have shown improvement in negative symptoms, cognition, and quality of life in schizophrenia patients. However, the biological mechanism/s of action of yoga in schizophrenia are not clear. The current study was aimed at exploring the effects of long-term (6 months) add-on yoga therapy on the immune inflammatory pathway in schizophrenia patients.

Methods: Sixty schizophrenia patients were randomized to add-on yoga therapy (YT=30) and treatment-as-usual (TAU=30) groups of which 21 patients in YT and 20 in TAU group completed the study. Blood samples and clinical assessments were obtained at baseline and at the end of 6 months. The plasma levels of nine cytokines (IL-2, IL-4, IL-5, IL-10, IL-12(p70), IL-13, GM-CSF, IFN-γ, and TNF-α) were quantified using multiplex suspension array. The clinical assessments included SAPS, SANS, BPRS, PSS, CGI, SOFS and WHOQUOL-BREF.

Results: Patients in the yoga group showed significant reductions in plasma TNF-α (Z = 2.99, p = 0.003) and IL-5 levels (Z = 2.20, p = 0.03) and greater clinical improvements in SAPS, SANS, PSS, and SOFS scores as compared to TAU group. Further, plasma TNF-α levels exhibited a positive correlation with negative symptoms (rs =0.45, p = 0.02) and socio-occupational functioning (rs =0.61, p = 0.002) in the YT group.

Conclusions: The findings of the study suggest that improvements in schizophrenia psychopathology with yoga interventions are associated with immuno-modulatory effects.

Keywords: Cytokines; Immunomodulation; Inflammation; Pharmacotherapy; Schizophrenia; Yoga therapy.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Antipsychotic Agents* / therapeutic use
  • Humans
  • Interleukin-5 / therapeutic use
  • Quality of Life
  • Schizophrenia* / drug therapy
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha
  • Yoga* / psychology

Substances

  • Antipsychotic Agents
  • Interleukin-5
  • Tumor Necrosis Factor-alpha